Legend Biotech (LEGN) has released an update.
Legend Biotech has reported robust second quarter results for 2024 with notable approvals for its CARVYKTI® treatment in multiple myeloma, showing strong sales and positive survival outcomes in clinical studies. The company’s financial health appears solid with a cash reserve of $1.3 billion, expected to sustain operations into 2026 when they predict achieving operating profit. These achievements, alongside the expansion of manufacturing capabilities, mark significant strides in Legend Biotech’s commitment to advancing cell therapy treatments.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
